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Abstract
 
The vascular endothelial growth factor (VEGF) receptor fetal liver kinase 1 (flk1; VEGFR-2,
KDR) is an endothelial cell–specific receptor tyrosine kinase that mediates physiological and
pathological angiogenesis. We hypothesized that an active immunotherapy approach targeting
flk1 may inhibit tumor angiogenesis and metastasis. To test this hypothesis, we first evaluated
whether immune responses to flk1 could be elicited in mice by immunization with dendritic
cells pulsed with a soluble flk1 protein (DC-flk1). This immunization generated flk1-specific
neutralizing antibody and CD8
 
 
 
 cytotoxic T cell responses, breaking tolerance to self-flk1 anti-
gen. Tumor-induced angiogenesis was suppressed in immunized mice as measured in an alginate
bead assay. Development of pulmonary metastases was strongly inhibited in DC-flk1–immu-
nized mice challenged with B16 melanoma or Lewis lung carcinoma cells. DC-flk1 immuniza-
tion also significantly prolonged the survival of mice challenged with Lewis lung tumors. Thus,
an active immunization strategy that targets an angiogenesis-related antigen on endothelium can
inhibit angiogenesis and may be a useful approach for treating angiogenesis-related diseases.
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Introduction
 
Tumor metastasis is the main cause for failure of conven-
tional cancer therapy, necessitating the reevaluation of
current cancer therapy strategies. Conventional approaches
for cancer immunotherapy usually target antigens expressed
by tumor cells and are aimed at eradicating tumor cells by
direct or indirect immunological attack (1–3). Despite the
identification of tumor-associated antigens and the demon-
strated effectiveness of immunotherapy in many experimen-
tal animal tumor models, immunotherapy currently has lim-
ited clinical utility for human cancers. The limitations of
cancer immunotherapy are thought to be due in part to
poor immunogenicity, immune tolerance, and escape of tu-
mor cells from immune surveillance through antigen modu-
lation, decreased MHC expression by tumor cells, lack of
 
costimulatory molecules, or secretion of immunosuppressive
molecules by tumor cells (4, 5). One possible alternative to
overcome these obstacles of conventional immunotherapy is
to target the blood vessels nourishing the growing tumor
cells rather than the tumor cells themselves.
Angiogenesis, the growth of new blood vessels from pre-
existing vasculature, is a tightly regulated process important
in fetal development and wound healing and in pathologi-
cal conditions such as tumor growth and metastasis (6, 7).
 
Vascular endothelial growth factor (VEGF)
 
*
 
 and its recep-
tors fetal liver kinase 1 (flk1; murine) and KDR (human)
play a critical role in regulating the process of normal and
pathological angiogenesis. Targeted inactivation of the gene
for VEGF or flk1 in mice results in embryonic lethality at
day 7.5 due to severely impaired vascular development (8,
9). The importance of VEGF and flk1/KDR in tumor an-
giogenesis is exemplified in studies using a dominant-nega-
tive flk1 receptor (10), neutralization of VEGF by mono-
clonal antibodies (11), neutralizing flk1/KDR mAb (12,
13) or flk1/KDR kinase inhibitors (14), all of which were
shown to inhibit angiogenesis and tumor growth. More-
over, overexpression of VEGF and KDR is strongly associ-
ated with invasion and metastasis in human malignant dis-
ease (15, 16). Therefore, overexpressed flk1/KDR could be
a potential target for tumor immunotherapy.
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 AP, alkaline phosphatase; DC, dendritic
cell; flk1, fetal liver kinase 1; VEGF, vascular endothelial growth factor. 
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Inhibition of Tumor Angiogenesis and Metastasis by Vaccination Against flk1
 
We have hypothesized that a therapeutically effective
immune response can be elicited that targets flk1 expressed
on tumor blood vessels and thus, inhibit tumor angiogene-
sis and growth. To test this hypothesis, we used a dendritic
cell (DC) immunization strategy, which has been success-
fully used in mice to overcome immune tolerance to other
antigens (17). In this report, we demonstrate that immuni-
zation with DCs pulsed with soluble flk1 induces neutral-
izing antibody and CD8
 
 
 
 cytotoxic T cell responses,
suppresses tumor angiogenesis, and strongly inhibits the de-
velopment of metastasis in two mouse models.
 
Materials and Methods
 
Tumor Cell Lines.
 
Lewis lung carcinoma cell line D122–96
(H-2
 
b
 
) was provided by Dr. L. Eisenbach (Weizman Institute of
Science, Rehovot, Israel). H5V endothelial cell line (H-2
 
b
 
),
which expresses both flk1 and MHC class I, was provided by Dr.
A. Vecchi (Istituto Mario Negri, Milan, Italy; reference 18).
Mouse endothelial cell line bEND.3 (H-2
 
d
 
), which expresses flk1
(19), was obtained from Dr. T. Sato (University of Texas South-
western Medical Center, Dallas, TX). Melanoma cell line B16
(H-2
 
b
 
), EL4 lymphoma cell line (H-2
 
b
 
), and the NK-sensitive
YAC-1 cell line were all purchased from American Type Culture
Collection. The cell lines were maintained in DMEM media (In-
vitrogen) containing 10% FCS (HyClone Laboratories).
 
Animals.
 
Female C57BL/6 mice, 6–8 wk of age, were pur-
chased from Harlan Sprague Dawley, Inc. and housed under
pathogen-free conditions.
 
Soluble flk1-AP Protein.
 
Construction of the expression plas-
mid vector Aptag-flk1, which contains the cDNA corresponding
to the extracellular domain of flk1 fused to alkaline phosphatase
(AP), was described previously (20). Soluble flk1-AP protein was
purified using an anti-AP affinity chromatography, followed by a
size exclusion chromatography. It was then subjected to SDS-
PAGE, and shown as a single band with molecular weight of 
 
 
 
180
KD (
 
 
 
95% purity). The purified protein could be recognized by a
flk1-specific monoclonal antibody, DC101 in Western blot. The
binding of flk1-AP to VEGF was examined by an ELISA, and the
protein was found to be active. The purified protein was tested for
endotoxin using the Pyrogent
 
®
 
 plus Limulus Amebocyte Lysate as-
say kit (BioWhittaker). All protein preparations used in animal
studies contained 
 
 
 
1.25 EU/ml of endotoxin.
 
Recombinant flk1-His Protein.
 
The flk1 insert from the Aptag-
flk1 vector was subcloned into the plasmid pET28a vector with a
polyhistidine-encoding sequence at the amino-terminal (BD Bio-
sciences/CLONTECH Laboratories, Inc.). The construct was
verified by automatic sequence analysis. The recombinant flk1-
His protein was expressed in 
 
Escherichia coli
 
, purified from inclu-
sion bodies by preparative electrophoresis, and assessed for purity
by SDS-PAGE and binding to VEGF by ELISA.
 
DC Generation.
 
DCs were generated from the bone marrow
as described with modifications (21). Briefly, C57BL/6 mice
were killed and bone marrow harvested from tibia and femurs.
Bone marrow cells were depleted of existing T cells, B cells, mac-
rophages, and granulocytes by incubation with a cocktail of anti-
bodies including anti-CD4 (GK1.5), anti-CD8 (2.43), anti-Ia
(B21–2), anti-B220 (RA3–3A1/6.1), and anti-Gr-1 (RB6–8C5/1;
all from BD PharMingen), for 30 min at 4
 
 
 
C and then with rab-
bit complement (Accurate Chemical) for additional 30 min at
37
 
 
 
C. The remaining cells were cultured in 10% FCS supple-
mented RPMI 1640 in the presence of GM-CSF (20 ng/ml) and
 
IL-4 (50 ng/ml; PeproTech) at 37
 
 
 
C, 5% CO
 
2
 
, for 9 d. Nonad-
herent cells were then harvested and confirmed to be mature DCs
by their morphology and phenotypic profile (CD40
 
 
 
, CD81
 
 
 
,
CD86
 
 
 
, Ia
 
 
 
, and CD14
 
 
 
) on flow cytometric analysis.
 
Antigen Pulsing of DCs and Immunization Protocol.
 
DCs were
pulsed with antigen, as described previously (22). Briefly, DCs
were washed twice in the serum-free medium AIM V (Invitro-
gen) and incubated with soluble flk1-AP protein or human AP
(50 
 
 
 
g/ml) in AIM V for 16 h. The cells were then washed twice
in AIM V before use for vaccination. For immunization, mice
were injected intravenously with 5 
 
 
 
 10
 
4
 
 flk1-AP-pulsed DCs,
AP-pulsed DCs, or PBS (200 
 
 
 
l) per mouse at 8–10 d intervals.
 
CTL Culture and Assay.
 
Mice were immunized three times
with DCs pulsed with flk1-AP (DC-flk1), DCs pulsed with AP
(DC-AP), or PBS as described above. CTL response was assessed
as described previously (23). Briefly, spleen cells were prepared
from immunized mice (two mice per group) and restimulated
with DCs pulsed with flk1-AP (at 100:1 effector/stimulator ratio)
in a 24-well plate for 5 d in RPMI 1640 (Invitrogen) with 10%
FCS. The CTL activity was tested in a 4-h 
 
51
 
Cr release assay
against a panel of target cells including flk1
 
 
 
 H5V endothelial
cells, flk1
 
 
 
 D122–96 tumor cells, flk1-AP-pulsed DCs, AP-pulsed
DCs, and NK-sensitive YAC-1 cells. The percentage cytotoxicity
was calculated using the formula: (experimental release 
 
 
 
 sponta-
neous release)/(maximum release 
 
 
 
 spontaneous release) 
 
 
 
 100.
 
Detection of Antibody Response.
 
Mice were immunized three
times with flk1-AP-pulsed DCs, AP-pulsed DCs, or PBS as de-
scribed above. Blood samples were collected from mice before
and 7 d after vaccinations. Anti-flk1 antibody in the sera was de-
tected by ELISA. Briefly, a 96-well plate was incubated with 200
ng/well of flk1-His protein overnight at 4
 
 
 
C. After three washes
with 0.1% Tween in PBS, 2% BSA was added to the plate and
incubated at room temperature for 1 h. Diluted sera were then
added to wells and incubated for 1 h. Wells were washed three
times and then incubated with 100 
 
 
 
l goat anti–mouse peroxi-
dase for 1 h. Wells were washed three times and then incubated
with 50 
 
 
 
l of 3,3
 
 
 
, 5,5
 
 
 
-tetra-methylbenzidine (TMB) substrate
(Kirkegaard and Perry Lab, Inc.) for 15 min. The reaction was
stopped by adding 50 
 
 
 
l of 1 M phosphoric acid and wells read at
450 nm on a microtiter plate reader. For flk1-VEGF blocking as-
says, wells were coated with 100 ng of recombinant human
VEGF
 
165
 
 (provided by Dr. P. Kussie, ImClone) overnight at 4
 
 
 
C.
Wells are blocked as described above and then incubated for 1 h
at room temperature with 100 ng of flk-AP that had been prein-
cubated for 2 h with various concentrations of sera from immu-
nized mice. Wells were washed and incubated with p-nitrophe-
nyl phosphate (PNPP; Sigma-Aldrich). Color was developed for
30 min at room temperature and was then read at 405 nm on a
microtiter plate reader.
 
Cell-based Ligand-binding Competition Experiments.
 
Cell-based
ligand-binding assays were performed as described with modifica-
tions (24). Flk1-expressing bEND.3 cells (10
 
5
 
 per well) were
grown in 24-well plates in DMEM 10% FCS for 48 h. Cells were
washed three times with binding buffer (DMEM with 0.1%
BSA). Pooled immune sera from DC-flk1–immunized mice or
from DC-AP–immunized mice and unlabeled recombinant hu-
man VEGF
 
165
 
 were serially diluted in binding buffer as indicated.
In a total volume of 400 
 
 
 
l/well, cells were incubated with the
samples for 4 h at 4
 
 
 
C. Cells were then washed with binding
buffer and incubated with 10 nCi [
 
125
 
I]VEGF (Amersham Phar-
macia Biotech) in 400 
 
 
 
l binding buffer per well for 1 h. After
incubation, cells were washed using cold PBS with 0.1% BSA.
Cells were harvested by adding 200 
 
 
 
l of 0.5 M NaOH. The ra- 
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dioactivity bound to the cells was determined in a Wizard 1470
gamma counter (PerkinElmer).
 
Alginate In Vivo Angiogenesis Assay.
 
An alginate bead assay
was designed to measure in vivo angiogenesis induced by tumor
cells (25). Lewis lung tumor cells were suspended in a 1.5% solu-
tion of sodium alginate and added drop by drop into a swirling
37
 
 
 
C solution of 250 mM calcium chloride. Alginate beads were
formed containing 
 
 
 
5 
 
 
 
 10
 
4
 
 tumor cells per bead. Mice were
anesthetized and four beads implanted subcutaneously through an
incision made on the dorsal side. Incisions were closed with sur-
gical clips. After 12 d, mice were injected intravenously with 100
 
 
 
l of FITC-dextran solution (20 mg/ml). Animals were killed af-
ter 20 min, beads removed, and incubated overnight at room
temperature in 1 ml of buffer (1 mM Tris-HCl, pH 8). The beads
were ground briefly with a hand-held mixer and an additional 1
ml of buffer was added. Samples were then vortexed and centri-
fuged at 1,500 rpm for 5 min. Fluorescence of the sample super-
natants was quantitated against a standard curve of FITC-dextran.
 
B16 Metastasis Model.
 
Mice were immunized three times
with flk1-AP–pulsed DCs, AP-pulsed DCs, or PBS as described
above. 10 d after the last immunization, mice were injected intra-
venously with 10
 
6
 
 B16 cells. Mice were killed based on the met-
astatic death in the control groups. Tumor load was assessed by
counting the tumor nodules on the lung surface.
 
Lewis Lung Metastasis Model.
 
Mice were immunized three
times with flk1-AP–pulsed DCs, AP-pulsed DCs, or PBS as de-
scribed above. 10 d after the last immunization, mice were chal-
lenged with an intrafootpad injection with 2 
 
 
 
 10
 
5
 
 of D122–96
tumor cells. When tumors reached 
 
 
 
5 mm in diameter, the tu-
mor-bearing leg was surgically removed. Mice were killed based
on the metastatic death in the control groups. Tumor load was
assessed by counting the tumor nodules on the lung surface. In
separate experiments, mice were monitored daily for survival.
 
In Vivo T Cell Depletion Experiment.
 
1 d before DC-flk1 im-
munization, mice received intraperitoneal injection of 0.5 mg of
either anti-CD4 (GK1.5), or anti-CD8 (clone 116), or control rat
IgG (Jackson ImmunoResearch Laboratories). To ensure com-
plete depletion of respective T cell population, one mouse from
each group was killed the next day and splenocytes were analyzed
by FACS
 
®
 
 after staining with FITC-conjugated anti-CD4 (L3T4)
and PE-conjugated anti-CD8 (Ly2; BD PharMingen). The same
depletion procedure was repeated every 2 wk to prevent recovery
of depleted T cell populations. The mice were immunized three
times with DCs pulsed with flk1-AP and then challenged with
Lewis lung tumor as described in the Lewis lung metastasis model.
Tumor load in the lungs were compared among the groups.
 
Mouse Pregnancy Experiment.
 
To test whether flk1 immuniza-
tion could affect mouse pregnancy by interfering with prenatal
angiogenic process, female mice were immunized with DCs
pulsed with flk1-AP or PBS as described above. In an additional
control, another group of mice were treated with intraperitoneal
injections of the anti-flk1 antibody DC101 (800 
 
 
 
g per injection,
twice weekly for 30 d; reference 12). Mice were then mated with
males and monitored daily for signs of pregnancy. Number of
pups of each delivery was recorded. The pups were also carefully
examined for signs of sickness and abnormality.
 
Wound Healing Experiment.
 
10 d after the last immunization
with flk1-AP–pulsed DCs, a full thickness wound, including the
panniculus carnous, was excised from the dorsum of each mouse.
A 1.60-cm
 
2
 
 circular defect was outlined 2.0 cm from the nape of
the animal’s neck using a fine-tipped marking pen. The defect
was created by elevating the skin and panniculus carnosus in the
center of the outlined defect using forceps, followed by excision
of the outlined area using microdissecting scissors. Wound area
was measured twice weekly. 15 d after this excision, mice were
killed, and scar tissues were removed for histological examination.
 
Histology.
 
Lung samples and scar tissues were fixed overnight
in 10% zinc formalin at 4
 
 
 
C, embedded in paraffin, and sectioned
at 5 
 
 
 
m onto saline-coated slides. Hematoxylin and eosin stain-
Figure 1. Flk1-specific neutralizing antibody induced by vaccination
with DCs pulsed with soluble flk1 protein. (A) Mice were immunized
three times with flk1-AP-pulsed DCs (DC-flk1), AP-pulsed DCs (DC-AP),
or PBS. Postimmunization sera (1:100 dilution) were analyzed for anti-
flk1 antibody using ELISA in plates coated with flk1-His protein. Mice
immunized with DC-flk1 exhibited significantly higher levels of anti-flk1
antibody compared with control groups. (B) Serially diluted sera from
immunized mice were coincubated with soluble flk1-AP protein and then
tested for binding to VEGF by ELISA. Results indicated that sera from
DC-flk1–immunized mice blocked binding of VEGF to soluble flk1 re-
ceptor. (C) Serially diluted sera from immunized mice were incubated
with flk1-expressing bEND.3 cells at 4 C for 4 h in a total volume of 0.4
ml. In parallel, the cells were incubated with a decreasing amount of unla-
beled VEGF (serially diluted from a 400 ng/ml solution). After incubation,
cells were washed and incubated with 10 nCi [125I]VEGF for 1 h at room
temperature. The cells were washed and counted in a   counter. Results
suggested that sera from DC-flk1–immunized mice blocked binding of
VEGF to flk1 expressed at the surface of endothelial cells. 
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ing was performed. Scar tissues from the wound healing study
were additionally stained with a Masson’s trichrome kit (Richard
Allen Scientific) according to manufacturer’s instructions.
 
Statistic Analysis.
 
All data including tumor counts and vessel
measurement were analyzed using Student’s 
 
t
 
 test with Sigma-
Stat v.2.03.
 
Results
 
Immune Tolerance to Self-flk1 Antigen Can Be Broken by
Immunization with DCs Pulsed with Soluble flk1.
 
C57BL/6
mice were immunized three times at 8–10 d intervals with
DCs pulsed with soluble flk1-AP protein (DC-flk1), DCs
pulsed with a control protein alkaline phosphatase (DC-
AP), or with vehicle alone (PBS).
Sera were collected from immunized mice and tested for
anti-flk1 antibody by ELISA in plates coated by flk1-His
protein. A strong antibody response was generated in DC-
flk1 vaccinated mice (Fig. 1 A). In contrast, anti-flk1 anti-
body was detected in only 1 of 10 mice from DC-AP
group and in none of the PBS group. Antibody titer was
significantly higher in all mice vaccinated with DC-flk1
compared with prevaccination sera (data not shown). No-
tably, the immune sera from DC-flk1 group inhibited the
binding of soluble flk1 receptor to VEGF by ELISA,
whereas the immune sera from DC-AP or PBS groups did
not show any signification inhibition (Fig. 1 B), demon-
strating the presence of a neutralizing anti-flk1 antibody.
The specificity and neutralizing activity of the anti-flk1
antibody was further evaluated in a [
 
125
 
I]VEGF binding
assay using flk1
 
 
 
 bEND.3 cells (Fig. 1 C). Immune sera
from DC-flk1 group strongly inhibited the binding of
[
 
125
 
I]VEGF to the native flk1 receptor on bEND.3 cells,
compared with control sera from DC-AP group.
To analyze the cellular immune response in mice immu-
nized with DC-flk1, splenocytes from the mice were har-
vested 10 d after the second boost immunization and
further stimulated in vitro by cocultivation with flk1-AP–
pulsed DCs for 14 d, followed by testing in a 4-h 
 
51
 
Cr re-
lease assay for CTL activity against flk1-positive and flk1-
negative targets. Splenocyte cultures from mice immunized
with DC-flk1 showed a significantly higher level of CTL
activity against the flk1-positive endothelial cell line H5V,
compared with DC-AP or PBS groups (Fig. 2 A). To de-
termine whether this CTL response was specific for flk1, T
cells from the DC-flk1 group were also tested against flk1-
AP-pulsed DCs, and AP-pulsed DCs as targets. Only the
DC-flk1-AP but not the DC-AP target cells were lysed by
these T cells, indicating the specificity for flk1 antigen (Fig.
2 B). Moreover, these T cells did not lyse Lewis lung carci-
noma or EL-4 lymphoma tumor cells, or the NK-sensitive
YAC-1 cell line. These results demonstrate that both flk1-
specific humoral and cellular immune responses can be in-
duced in mice by immunization with DC-flk1.
DC-flk1–immunized mice appeared generally healthy,
gained normal weight, and no gross toxicity was observed.
However, breeding experiments revealed a striking effect
of DC-flk1 immunization on pregnant female mice. Fe-
male mice were immunized on days 0, 10, and 20 and
mated with nonimmunized male mice 10 d after the final
immunization. Only 20% of DC-flk1–immunized mice
became pregnant, compared with a 70% pregnancy rate in
the control group. Moreover, the mean litter size was sig-
nificantly smaller in the DC-flk1 group (2 vs. 6) compared
with the PBS control group (Table I). The small number of
Figure 2. Flk1-specific CTL
responses induced by vaccination
with DC-flk1. (A) Mice were
immunized three times with
DC-flk1, DC-AP, or PBS. Sple-
nocytes were harvested and
restimulated in vitro with flk1-
AP–pulsed DCs for 5 d. CTL
activity against flk1  endothelial
cells was assessed in a standard
51Cr release assay using H5V en-
dothelial cell line as target.
Higher CTL activity was de-
tected in DC-flk1–immunized
mice compared with DC-AP–
immunized or PBS control mice.
(B) T cells cultured from DC-flk1–immunized mice were further analyzed for their antigen specificity in the 51Cr release assay using the following targets:
flk1-AP-pulsed DCs, AP-pulsed DCs, flk1-negative tumor cell lines Lewis lung (D122–96) and EL4, and YAC-1. Results indicated that CTLs induced
in DC-flk1–immunized mice were specific to flk1 antigen and showed no cytotoxicity against flk1-negative tumor cell lines.
 
Table I.
 
Inhibition of Female Reproductive Function After 
Vaccination with DC-flk1
 
Treatment
 
a
 
No. of pregnancies Mean litter no.
PBS 7/10 6
DC-flk1 immunization 2/10 2
DC101 treatment 3/10 3
 
a
 
Female mice were immunized with flk1-AP–pulsed DCs or vehicle
alone as described above. In an additional control group, mice were
treated with intraperitoneal injections of the anti-flk1 antibody DC101
(800 
 
 
 
g per injection, twice weekly for 30 d) as a control. Mice were
then mated with males and monitored daily for signs of pregnancy.
Number of pups of each delivery was also recorded. 
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pups from the DC-flk1–immunized mice were either still-
born or died within 10 d after birth and were found to
have massive hemorrhage in all organs. Similar results were
observed in a group of female mice treated with the neu-
tralizing anti-flk1 monoclonal antibody DC101 (12). These
data indicate an inhibitory effect of DC-flk1 immunization
on fetal development.
 
Inhibition of Tumor Angiogenesis In Vivo by DC-flk1 Vacci-
nation.
 
To determine whether the anti-flk1 immune re-
sponses could inhibit tumor-induced angiogenesis, we
conducted an in vivo angiogenesis assay using alginate
 
beads. Lewis lung tumor cells encapsulated alginate beads
were implanted subcutaneously in DC-flk1–vaccinated
mice. Growth factors produced by the encapsulated tumor
cells induced vascularization of the beads, which was then
measured by uptake of FITC-dextran. Beads removed
from control mice after 12 d were extensively vascularized
whereas beads from DC-flk1–immunized mice were es-
sentially avascular (Fig. 3). Quantitative analysis of tumor
cell–induced vascularization decreased by 65% in mice
vaccinated with DC-flk1 compared with DC-AP group
(
 
P
 
 
 
 
 
 0.01).
Figure 3. DC-flk1 vaccination inhibits
tumor-induced angiogenesis. Mice were
immunized three times with DC-flk1, or
DC-AP. Alginate beads containing 5   104
Lewis lung tumor cells were then implanted
subcutaneously into the mice. 12 d later,
mice were injected intravenously with
FITC-dextran. Beads were then surgically
removed and FITC-dextran quantitated.
Mean   SE of n   12 mice/group. In a
negative control, beads containing no tu-
mor cells (blank) were implanted in naive
mice. On the right panel, pictures of repre-
sentative samples of beads from each group
were shown.
Figure 4. Lewis lung tumor me-
tastasis can be inhibited by DC-flk1
vaccination. (A) Mice were immu-
nized three times with DC-flk1,
DC-AP, or PBS and then challenge
with Lewis lung tumor cells intra-
footpad. The primary tumor was
surgically removed when it reaches
 5 mm in diameter. Mice were
killed based on the metastatic death
in the control groups, and lungs
were weighed and assessed for tumor
load. P   0.01 by Student’s t test.
(B) Pictures of representative lung
samples from each group. (C) Histo-
logical examination (H&E staining)
of lung samples from each group.
Original magnification:  100. 
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DC-flk1 Vaccination Inhibits Lewis Lung Pulmonary Me-
tastasis.
 
To determine whether active immunization
against flk1 could inhibit tumor metastasis, we tested im-
munized mice in a metastasis model of Lewis lung carci-
noma. Mice immunized with flk1-AP–pulsed DCs devel-
oped significantly reduced numbers of metastases in the
lungs (P   0.01) compared with mice immunized with ei-
ther AP-pulsed DCs or PBS (Fig. 4, A and B). Most signif-
icantly, 6 of 10 mice were found to be tumor-free in the
DC-flk1–immunized group, whereas all mice in the two
control groups developed extensive pulmonary metastases.
Macroscopic observations were further confirmed by mi-
croscopic examination of lung samples showing significant
reduction or complete absence of tumor cells in the lungs
of DC-flk1–immunized mice, whereas extensive tumor
infiltration was found in lungs of control groups (Fig. 4 C).
In addition to examination of tumor metastasis in immu-
nized mice, a similar experiment was conducted to evalu-
ate the effect of flk1 immunization on survival. As shown
in Fig. 5, while all mice had died of tumor by day 63 in
both control groups, 40% mice in the DC-flk1 group sur-
vived over 200 d. The other 60% of DC-flk1 group died
almost as quickly as the control mice, suggesting that it was
“all or none” protection.
DC-flk1 Vaccination Inhibits Metastasis Induced by B16
Melanoma. DC-flk1 immunization was also tested in a
B16 melanoma model. After three immunizations with
flk1-AP–pulsed DCs at days 0, 10, and 20, mice were chal-
lenged with an intravenous injection of B16 tumor cells. As
shown in Fig. 6, DC-flk1 immunization significantly in-
hibited the formation of lung metastases compared with
PBS or DC-AP control groups (P   0.01). Interestingly,
Figure 5. Survival advantage in mice immunized with DC-flk1 after a
tumor challenge. Animals (n    10) were immunized with DC-flk1,
DC-AP, or PBS. The experiment is similar to that described Fig. 3 A, ex-
cept that the animals were not killed but were monitored for survival.
The data is expressed as percentage of survival as function of time. Sur-
vival for the mice immunized with DC-flk1 was significantly prolonged
over the DC-AP and PBS controls.
Figure 6. Inhibition of B16 tu-
mor metastasis by DC-flk1 vaccina-
tion. (A) Mice were immunized
with DC-flk1, DC-AP, or PBS, be-
fore challenged with intravenous in-
jection of B16 tumor cells. Mice
were killed 30 d after tumor inocu-
lation and the lungs were assessed for
tumor load. P   0.01 by Student’s t
test. (B) Pictures of representative
lung samples from each group. (C)
Histological esamination of lung
samples from each group. Original
magnification:  100.1581 Li et al.
DC-AP group also showed a certain level of metastatic in-
hibition compared with PBS group.
CD8  T Cells Play a Critical Role in Antitumor Response
Induced by DC-flk1 Vaccination. To determine which T
cell population (i.e., CD4, CD8, or both) was responsible
for the antitumor activities, we conducted an in vivo T cell
depletion assay in mice vaccinated with flk1-AP-pulsed
DCs in the Lewis lung metastatic model (23). Mice were
treated with either anti-CD4, anti-CD8, or control Ab be-
fore vaccinations with DC-flk1 and again 2 wk later. De-
pletion of respective T cell population was confirmed by
FACS® analysis of splenocytes of one mouse from each
group. The antitumor effect of vaccination against flk1 was
abrogated in CD8-depleted but not in CD4-depleted mice
(Fig. 7). These results suggest that the CD8 population is
mainly responsible for the T cell–mediated anti-flk1 im-
mune response.
Wound Healing Is Not Affected by DC-flk1 Vaccination.
As described above, breeding experiments indicated an ef-
fect of DC-flk1 immunization on prenatal development.
To further examine whether active immunization against
flk1 has an effect on normal physiological angiogenesis,
we analyzed wound healing in immunized mice using
an excisional cutaneous wound model. Full-thickness
wounds were created on the dorsum of control or DC-
flk1–immunized mice 10 d after three immunizations on
days 0, 10, and 20. Wound areas were measured twice
weekly until they were completely healed. No significant
difference in wound healing was observed between DC-
flk1–immunized and control mice (Fig. 8 A). Microscopic
examination of wound tissues revealed no difference in
wound epithelialization, vascularity or collagen deposition
(Fig. 8 B).
Figure 7. CD8  CTL play a major role in antitumor response induced
by DC-flk1. Mice were treated with anti-CD4, CD8, or control Abs be-
fore they were immunized DC-flk1. In an additional control group, mice
were not immunized. Mice were then challenged with Lewis lung tumor
intrafootpad. The primary tumor was surgically removed when it reached
 5 mm in diameter. Mice were killed based on the metastatic death in
the control groups. P   0.01 by Student’s t test.
Figure 8. Cutaneous wound healing is
not affected by DC-flk1 vaccination. A full-
thickness excisional wound was created in
DC-flk1 and untreated mice. Wound areas
were measured twice weekly until wounds
were completely healed (A). Wound scar
tissues at day 15 from both groups were an-
alyzed by histology (B). Top: hematoxylin
and eosin staining; bottom: trichrome stain-
ing for collagen. Original magnification:
 100. No difference was found between
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Discussion
By using DCs to break tolerance to self-antigen, we
demonstrate that active immunization against the VEGF
receptor flk1 can inhibit tumor angiogenesis and metastasis
in mice. We chose flk1 as the molecular target for these
studies because of its recognized importance in angiogene-
sis and tumor growth. These results provide strong proof of
concept that an active immunization approach against an
angiogenic target can be effectively used for tumor therapy.
Our data are consistent with those of other studies that
have used antagonists of the VEGF pathway to inhibit tu-
mor-associated angiogenesis (10–14). Recently, Wei et al.
reported that cross-immunization with xenogeneic endo-
thelial cells was effective in inducing an endothelial cell–
specific immunity and protecting mice from tumor chal-
lenge. In their study, peptides within  v integrin and
EGFR-2 were identified as the possible antigen epitopes
(26). Plum et al. showed that administration of a liposomal
FGF-2 peptide vaccine led to abrogation of FGF-mediated
angiogenesis and tumor development in mouse models
(27). These studies suggest that angiogenesis-directed im-
munotherapy approach may potentially extend to other an-
giogenic targets such as VEGF, the Tie2 receptor (28), an-
giopoietin-1 (29, 30),  v 3 (31), and VE-cadherin (32).
We detected a strong CTL response after DC-flk1 im-
munization. It is likely that flk1-specific CTLs exert antitu-
mor effect by destroying endothelial cells in the neovascul-
ture surrounding tumor nodules. Notably, flk1-specific
neutralizing antibody was also present in the sera of immu-
nized mice. The antibody effectively blocked the binding
of VEGF to native flk1 at the surface of endothelial cells.
Blockade of the VEGF-flk1 pathway could play an impor-
tant role in the suppression of angiogenesis observed in
DC-flk1–immunized mice. In the in vivo T cell depletion
experiment, depletion of CD8  T cells abrogated the anti-
tumor effect in the Lewis lung metastasis model whereas
CD4  T cell depletion had a marginal effect. This result
suggested a dominant role of CD8  CTLs in the antitumor
activity while the role of flk-1 neutralizing antibody could
not be excluded. This finding is consistent with the notion
that antitumor immunity depends on CD8  T cells in
many experimental tumor models (33). Given that an anti-
flk1 neutralizing antibody response occurred in DC-flk1–
immunized mice, however, we were surprised that CD4 
T cell depletion did not affect the antitumor activity. One
possible explanation for this observation is that the anti-
body induced by DC-flk1 immunization recognized a flk1
epitope that is CD4 independent. In the study by Wei et
al., CD4  T cells and antibody were reported to be impor-
tant in the antitumor activity induced by xenogenic endo-
thelial cell vaccine (26). Plum et al. found that an anti-FGF-2
antibody was induced after immunization with liposomal
FGF-2 peptide vaccine (27). The importance of CD8 
versus CD4  T cell immunity in these studies may have
been determined by the use of different target antigens, ad-
juvants, and routes of immunization.
Flk1 is expressed in normal vascular endothelium albeit in
lower levels compared with that in tumor vasculature and is
important in fetal development (9, 34–37) and in physiologi-
cal angiogenesis such as wound healing (34, 38, 39). One
important observation in our studies was the adverse effect of
DC-flk1 immunization on mouse pregnancy. This finding is
consistent with the role of angiogenesis in multiple aspects of
female reproductive function and fetal development. In non-
pregnant adult mice, however, vaccination did not induce
observable toxicity. Wound healing was not affected in the
immunized mice. This result is compatible with the report
that the angiogenesis inhibitor vasostatin does not impair
wound healing at tumor-inhibiting doses (40). The lack of
toxicity suggests a different sensitivity of malignant tumor
growth than physiologic wound healing to inhibition of an-
giogenesis. Another possible explanation is that the level of
expression of flk1 in quiescent normal vascular endothelium
may be too low to be recognized by flk1-specific CTLs.
As an antiangiogenesis therapy, active immunization af-
fords the opportunity to elicit a sustained effect in chronic
disease settings. In contrast, antagonist drug therapies must
be administered for long periods of time. In our experi-
ments, the anti-flk1 immune response was monitored as
long as 20 wk after the last booster immunization and was
found to gradually diminish after the last immunization but
could be restored to a therapeutic level with 1–2 booster
immunizations (data not shown). Thus, the immune re-
sponse against an angiogenesis-related target (and any ef-
fects associated with the immune response) may be short
lived but could be recalled by repeated immunizations. In
the context of immunotherapy, this approach benefits from
the advantages of targeting an antigen expressed on non-
transformed cells, i.e., endothelial cells. Endothelial cells do
not bear the problems associated with targeting antigens on
tumor cells, such as genetic instability, mutations, or loss of
antigen expression. Another advantage is that one single
antiangiogenesis vaccine may be used against multiple tu-
mor types. This notion is supported by this study and oth-
ers (26, 27). In conclusion, angiogenesis-targeted immuno-
therapy offers the potential for a new approach to
treatment of cancer and other angiogenesis-related diseases.
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